Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW685698X Morning · 1 trial · 1 indication
Mean change from baseline in daily trough (pre study treatment and pre bronchodilator) PEF during the 28 day treatment period with GW685698X 100mcg once daily in the morning compared with GW685698X 100mcg once daily in the evening by inhalation via DISKHALER.
| Arm | Type | Description |
|---|---|---|
| GW685698X (fluticasone furoate) 100mcg Morning | EXPERIMENTAL | - |
| GW685698X (fluticasone furoate) 100mcg Evening | EXPERIMENTAL | - |
| GW685698X (fluticasone furoate) 250mcg Evening | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| GW685698X (fluticasone furoate) 100mcg Morning | DRUG | GW685698X inhaled once daily in the morning plus placebo in the evening for 28 days |
| GW685698X (fluticasone furoate) 100mcg Evening | DRUG | GW685698X inhaled once daily in the evening fplus placebo in the morning for 28 days |
| GW685698X (fluticasone furoate) 250mcg Evening | DRUG | GW685698X inhaled once daily in the evening plus placebo in the morning for 28 days |
| Placebo | DRUG | Placebo inhaled twice daily (morning and evening) for 28 days |
Inclusion Criteria: * Outpatients aged between 16- 65 years. * Male and female; female subjects must be non-child bearing potential or of childbearing potenetial with negative pregnancy test and willing to use acceptable contraceptive methods * Documented clinical history of persistent asthma first...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
GW685698X Morning is an investigational inhaled asthma treatment containing fluticasone furoate at a 100 microgram dose, given once daily in the morning. It is a small molecule developed by GSK plc for persistent bronchial asthma and was studied in a Phase 2 trial. It is not an approved product.
GW685698X Morning was studied for the treatment of persistent bronchial asthma in patients aged 16 years and older. The Phase 2 trial enrolled 669 participants with asthma across multiple countries. Because the program remains investigational, the drug has no approved indication.
GSK plc, which trades under the ticker GSK, is the developer of GW685698X Morning. The company sponsored the Phase 2 study of the 100 microgram once daily morning dose in asthma. GSK is the originator of the fluticasone furoate compound.
GW685698X Morning is in Phase 2 development. One Phase 2 trial has been completed, and no trials are currently active. The study was randomized, double blind, and placebo controlled, and it evaluated the 100 microgram morning dose over 28 days in asthma patients.
GW685698X Morning was evaluated in the completed Phase 2 trial NCT01499446, titled a study of GW685698X 100mcg administered once daily either in the morning or the evening and GW685698X 250mcg once daily in the evening via DISKHALER for 28 days in subjects with persistent bronchial asthma. It enrolled 669 participants across 13 countries.